Sumit Sharma, MD
Retina Specialist · Cleveland, OHNPI 1801025697
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Eyepoint US, Inc. at 26.8% of the total. Among retina specialist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $1225.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$114K
- Genentech USA, Inc.$66K
- Regeneron Healthcare Solutions, Inc.$45K
- Astellas Pharma US Inc$33K
- Regeneron$28K
- F. Hoffmann-la Roche AG$27K
- plus $114K from 18 others
Across 202 payments — averaging $5520.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$855K
- Gilead$139K
- Roche TCRC, Inc.$81K
- F. Hoffmann-la Roche AG$14K
- AstraZeneca$13K
- Regeneron$12K
- plus $2K from 1 others
What the payments were for
- Consulting fees$245,31457%
- Speaking & faculty fees$150,91235%
- Travel & lodging$19,9815%
- Food & beverage$11,5343%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 76 | $114,426 |
| Genentech USA, Inc. | 44 | $66,239 |
| Regeneron Healthcare Solutions, Inc. | 23 | $44,866 |
| Astellas Pharma US Inc | 20 | $32,942 |
| Regeneron | 25 | $28,215 |
| F. Hoffmann-la Roche AG | 9 | $27,427 |
| Harrow Eye, LLC | 11 | $21,537 |
| AbbVie(2 entities) | 22 | $18,831 |
| Bausch & Lomb Americas Inc. | 35 | $13,956 |
| Merck | 9 | $10,845 |
| Alimera Sciences, Inc. | 19 | $10,579 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $10,280 |
| Genentech, Inc. | 7 | $9,546 |
| Apellis Pharmaceuticals, Inc. | 16 | $6,854 |
| Carl Zeiss Meditec USA, Inc. | 5 | $3,803 |
| ANI Pharmaceuticals, Inc. | 5 | $3,084 |
| Astellas Pharma Global Development | 1 | $3,054 |
| Carl Zeiss Meditec, Inc. | 2 | $723 |
| Novartis | 2 | $172 |
| Coherus Oncology, Inc. | 1 | $136 |
| Gilead | 1 | $78 |
| Neurotech Pharmaceuticals, Inc. | 1 | $73 |
| Mallinckrodt Enterprises LLC | 1 | $41 |
| Samsara Vision | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- YUTIQ$87,061
- Izervay$31,891
- EYLEA HD$31,037
- EYLEA$30,286
- Lucentis$28,213
- EYP-1901$25,912
- VABYSMO$23,463
- TRIESENCE$21,341
- OZURDEX$16,409
- SUSVIMO$12,304
- XIPERE$11,716
- Iluvien$10,239
- RETISERT$5,250
- LOTEMAX SM$4,611
- CIRRUS 6000 with AngioPlex$3,038
- CIRRUS HD-OCT$3,038
- PURIFIED CORTROPHIN GEL$2,853
- IHEEZO$2,800
- QUATERA 700$2,430
- CALLISTO eye$2,430
How this compares
$427,740 in reported general payments places this provider in the 95th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 148 | $10,825 |
| Prednisolone Acetate | 227 | $10,484 |
| IlevroNepafenac | 22 | $8,690 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $2,602 |
| Valganciclovir Hcl | 11 | $2,148 |
| Ketorolac Tromethamine | 60 | $1,699 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 126 | $1,521 |
| ValacyclovirValacyclovir Hcl | 29 | $1,208 |
| Atropine Sulfate | 50 | $955 |
| Ciprofloxacin Hcl | 71 | $819 |
| Latanoprost | 84 | $787 |
| Timolol Maleate | 59 | $350 |
| Dorzolamide Hcl | 13 | $335 |
| Brimonidine Tartrate | 45 | $298 |
| Prednisone | 31 | $155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlevro | $172 | $8,69022 claims |
| AbbVieCombigan | $18,831 | $2,60215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 retina specialist providers in Ohio.
Other retina specialist in Cleveland
- Aleksandra RachitskayaCleveland$303K
- Katherine TalcottCleveland$272K
- Suber HuangCleveland$124K
- Ananth SastryCleveland$44K
- Phoebe LinCleveland$22K
- Warren SobolCleveland$5K
- Mark SeralyCleveland$3K
- Abhishek NaiduCleveland$3K
- Mary-Grace ReevesCleveland$2K
- Joseph ConeyBeachwood$980K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.